The FDA has announced its acceptance of an application for Exparel, a long-acting bupivacaine for postsurgical pain management produced by Pacira Pharmaceuticals, according to a Trading Markets report.
The drug consists of bupivacaine encapsulated in DepoFoam, the company's technology that allows the analgesic effects to last longer. The drug is designed to provide 72 hours of post-surgical non-opioid pain relief, according to the website. The FDA expects to complete its review of Exparel by July 2011.
Read the Trading Markets report on Exparel.
Read more on anesthesia:
-Anesthesiologist Tasks Colleagues With Peri-Operative Improvement in 2011
-Blocking Receptor Might Help Control Post-Surgery Pain and Inflammation
-10 Anesthesia Studies Making Recent Headlines
The drug consists of bupivacaine encapsulated in DepoFoam, the company's technology that allows the analgesic effects to last longer. The drug is designed to provide 72 hours of post-surgical non-opioid pain relief, according to the website. The FDA expects to complete its review of Exparel by July 2011.
Read the Trading Markets report on Exparel.
Read more on anesthesia:
-Anesthesiologist Tasks Colleagues With Peri-Operative Improvement in 2011
-Blocking Receptor Might Help Control Post-Surgery Pain and Inflammation
-10 Anesthesia Studies Making Recent Headlines